Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Three-arm, Parallel Group, Single Dose Comparative PK, PD, Safety and Immunogenicity Study Comparing ADL-018 With US-licensed XOLAIR and EU-Approved XOLAIR in Healthy Adult Subjects

NCT05413161 is registered in ClinicalTrials.gov with Kashiv BioSciences, LLC as lead sponsor.

NCT NCT05413161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05413161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Three-arm, Parallel Group, Single Dose Comparative PK, PD, Safety and Immunogenicity Study Comparing ADL-018 With US-licensed XOLAIR and EU-Approved XOLAIR in Healthy Adult Subjects
Lead sponsor
Kashiv BioSciences, LLC
Phase
Phase 1
Overall status
Completed
Start date
July 7, 2022
Completion date
June 30, 2023
Enrollment
306 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy